Clinical Trial Update: A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety of Navitoclax (ABT-263) in combination with etoposide and cisplatin in patients with solid tumors; the trial is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Etoposide (Etoposide)
• Navitoclax (navitoclax)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED